FDA Brief

Warning letters Drugs

FDA warning letter to

Canada Med Stop

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.

What happened

FDA reviewed Canada Med Stop's website in August 2025 and found it offered compounded semaglutide drug products. The site claimed the products had “The same active ingredient in branded weight loss medications,” called them “FDA-Approved Medication,” and used “GENERIC.” FDA says compounded drugs are not FDA-approved, so these claims are false or misleading and make the products misbranded.

What FDA found

  1. The website said the compounded semaglutide had the same active ingredient as branded weight-loss medicines, implying it was the same as an FDA-approved product.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website called compounded semaglutide “FDA-Approved Medication” even though compounded drugs are not FDA-approved.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The website used “GENERIC” in a way FDA says falsely implies the compounded product is the same as an FDA-approved drug.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. The company introduced or delivered misbranded drugs into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  5. Receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Canada Med Stop to take immediate action, including stopping use of the cited claims, and to send a written response within 15 working days describing the steps taken and how it will prevent recurrence, with supporting documents. If it cannot fully address the matter within that time, it must state why and give a timeline.

Who should pay attention

  • telehealth and online pharmacies selling compounded semaglutide
  • compounding pharmacies and marketers making FDA-approval or generic claims
  • U.S. consumers and clinicians comparing compounded products with approved semaglutide

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low